Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 2 | 3 | — | — | — | 4 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
Small cell lung carcinoma | D055752 | — | — | 1 | 1 | — | — | — | 1 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | 1 | — | — | — | 1 |
Drug common name | SATOREOTIDE TRIZOXETAN |
INN | satoreotide trizoxetan |
Description | Satoreotide trizoxetan is a protein pharmaceutical. It is currently being investigated in clinical studies. |
Classification | Protein |
Drug class | peptides: inhibition of growth hormone release; chelating agents |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2ccc(NC(N)=O)cc2)NC(=O)[C@H](Cc2ccc(NC(=O)[C@@H]3CC(=O)NC(=O)N3)cc2)NC(=O)[C@H](NC(=O)[C@H](Cc2ccc(Cl)cc2)NC(=O)CCC(C(=O)O)N2CCN(CC(=O)O)CCN(CC(=O)O)CC2)CSSC[C@@H](C(=O)N[C@H](Cc2ccc(O)cc2)C(N)=O)NC1=O |
PDB | — |
CAS-ID | 1638746-88-9 |
RxCUI | — |
ChEMBL ID | CHEMBL4297532 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 3M7TX701A4 (ChemIDplus, GSRS) |